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a B s t r a C t
Background: Garlic is a widely used herbal product for 
hypertension. Previous meta-analyses on the effect of garlic 
on blood pressure (BP) have been contradictory however. 
We hypothesised that methodological deficiencies may have 
contributed to this disagreement. We therefore evaluated 
whether trials reporting on the effect of garlic on BP had 
sufficient methodological qualities and a proper description 
of BP determination.
methods: medline, emBase, amed, the CoCHrane 
library, iBids and CinaHl were systematically searched 
for trials reporting on the effect of garlic on BP. Both the 
methodological quality and the quality of blood pressure 
measurement were appraised using predefined quality 
scores.
results: 32 studies were identified. of these studies, 13 
were included previously by other meta-analyses. the 
methodological quality of the studies was poor. only four 
trials had adequate allocation concealment, no single trial 
reported an intention-to-treat analysis and blinding of the 
evaluators was done in three trials only. moreover, half of 
the studies did not report any data on BP measurement. 
no trials reported on the arm level. Body position was 
described most often. all trials fulfilling a predefined cutoff 
point were conducted in normotensive subjects.
Conclusion: the effect of garlic on blood pressure cannot 
be ascertained. Previous meta-analyses have been based 
on trials with inadequate study designs, methodological 
deficiencies and with too little information about blood 
pressure measurement. in our view, use of garlic cannot be 
recommended as antihypertensive advice for hypertensive 
patients in daily practice.
K e y W o r d s
Blood pressure, hypertension, garlic, systematic review, 
quality analysis
i n t r o d U C t i o n
For the treatment of hypertension, non-pharmacological 
therapeutic advice is the initial therapeutic approach in 
patients with an increased cardiovascular risk.1 A number 
of such lifestyle recommendations clearly reduce blood 
pressure, e.g. weight reduction and regular physical 
activity.1 Food supplementation could provide another, less 
strenuous non-pharmacological intervention.
Garlic is the second most used herb taken by patients 
with cardiovascular disease.2 Moreover, garlic might lower 
blood pressure via the conversion of garlic-derived organic 
polysulphides into hydrogen sulphide by the red blood cell 
leading to vasorelaxation.3 It could therefore be a potential 
target as an antihypertensive food supplement.
Indeed, several trials suggest possible short-term effects of 
garlic on cardiovascular risk factors.4 The effects of garlic 
on blood pressure specifically have been summarised in 
three systematic reviews.4-6 However, the results were 
contradictory. This phenomenon has been evaluated 
previously by Linde et al.7 In their analysis on discordant 
conclusions of systematic reviews in complementary 
medicine, they concluded that these differences were 
mostly due to differences in inclusion and exclusion 
criteria. We wondered whether this could also be explained 
by the different approaches to appraise trial quality,8 
because trials in complementary medicine have low 
methodological quality9 and because these deficiencies may 
translate into biased findings in systematic reviews.10 
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Besides, none of these reviews4-6 looked at the quality 
of blood pressure measurement. Recently, Wood et al. 
demonstrated that bias in intervention effects is only seen 
in trials using subjective outcomes, i.e. physician assessed 
disease outcome.11 During blood pressure measurements 
many errors can occur resulting in varying blood pressures 
making it amenable to faulty outcomes.12 Thus when 
addressing the bias in blood pressure trials introduced 
by methodological deficiencies, proper blood pressure 
measurements seem to be an additional quality criterion.
We therefore conducted an analysis of the methodological 
quality of trials reporting on the effect of garlic on blood 
pressure using multiple strict quality criteria. The present 
study aims to answer the following four questions:
Does garlic lower blood pressure in humans?• 
What is the methodological quality of human trials • 
measuring the effect of garlic on blood pressure?
What information about criteria for blood pressure • 
measurements is presented in these garlic studies?
Did the inclusion of methodologically poor studies • 
affect the conclusions of previous systematic reviews?
m e t H o d s
literature search
MEDLINE (1966-2008), EMBASE (1980-2008), CINAHL 
(1982-2008), IBIDS (2008), AMED (1985-2008) and the 
COCHRANE library were searched from March 2008 until 
May 2008 using search strategies mentioned in table 1. The 
search was last updated in January 2009 by two reviewers 
independently. References from garlic reviews and eligible 
trials were searched for additional articles.
 
selection criteria
Studies in adults measuring the effect of garlic on blood 
pressure were considered eligible. Inclusion was limited 
to studies lasting more than eight weeks and with more 
than 20 participants. In crossover trials each parallel arm 
had to last more than eight weeks. Trials were selected 
independently by two reviewers on the basis of abstracts. 
data extraction
Two reviewers identified eligible trials. Data extraction 
and quality assessment were done by two reviewers. When 
results of a scoring card (see: quality analysis) deviated 
more than one point, a third independent reviewer was 
consulted. Differences were resolved by consensus. In 
case of different conclusions, consensus could always be 
reached.
Quality analysis
Both the methodological quality and the quality of blood 
pressure measurement were assessed using two different 
scoring systems.
Methodological quality was assessed using a scoring card 
derived from the Cochrane checklist ‘the assessment of 
a randomised trial’.13 The card consisted of nine items 
mentioned in table 2. A trial had to describe each item 
specifically. Moreover, both the number as well as the 
reasons for dropping out had to be recorded. Trial arms 
had to be similar in age, sex, blood pressure and modifying 
factors (smoking, diabetes, hypercholesterolaemia, 
overweight, alcohol, cardiovascular comorbidity; at least 
four mentioned). Each study could score a maximum of 
nine points.
table 1. Search strategy for each search engine
Medline ((((blood pressure) OR (blood pressure determination) OR (hypertension)) OR (‘Blood Pressure Determination’Mesh 
OR ‘Blood Pressure’Mesh OR ‘Hypertension’Mesh)) AND ((vinyl dithiin) OR (thiosulfinates) OR (diallyl derivative) OR 
(s-allyl cysteine) OR (kyolic) OR (kwai) OR (knoblauch) OR (garlic oil) OR (garlic extract) OR (dipropyl disulfide) OR 
(dipropyl disuphide) OR (diallyl disulfide) OR (diallyl disulphide) OR (allyl mercaptan) OR (alliinase) OR (allicin) 
OR (alisat) OR (ajoene) OR (ajo) OR (allium sativum) OR (garlic) OR (‘Garlic’Mesh))) AND ((HumansMesh) AND 
(adultMeSH:noexp OR middle ageMeSH OR (middle ageMeSH OR agedMeSH) OR agedMeSH OR aged, 80 and overMeSH))
EMBASE (‘human-’ / all SUBHEADINGS in DEM,DER,DRM,DRR) and (‘blood-pressure’ / all SUBHEADINGS in 
DEM,DER,DRM,DRR) and (‘garlic-’ / all SUBHEADINGS in DEM,DER,DRM,DRR)
CINAHL (‘Blood-Pressure’ / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE) and (‘Garlic-’ / all TOPICAL 
SUBHEADINGS / all AGE SUBHEADINGS in DE)
IBIDS +garlic +’blood pressure’
Cochrane library Garlic and blood pressure
table 2. Methodological quality of the selected trials 
(n=32) using the nine quality criteria*
Cochrane criterion number of studies 
fulfilling criterion 
Allocation concealment 4 
Randomisation 28
Patients blinded 24
Researchers blinded 24
Evaluators blinded 3
Comparable groups 10
Adequate lost-to-follow-up analysis 15
Intention-to-treat analysis 0
Groups receiving same treatment 27
*dutch Cochrane Centre: checklist for bias assessing of randomised 
controlled trials. www.cochrane.nl. accessed 21 July 2008.
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Roche et al.14 have reported on the quality of the blood pressure 
measurement in medical literature. During a preliminary 
data analysis, however, it became clear that no single study 
sufficiently fulfilled the criteria used in that study. Therefore, 
from the list used by Roche et al., five essential criteria 
were formulated based on a priorisation procedure (table 3). 
The methodology section of each trial was screened for the 
description of blood pressure measurement by two reviewers 
independently. A study could score a maximum of five points 
if each criterion was written specifically.
Different study designs were used; 21 double-blind, 
randomised, placebo-controlled, parallel trials;15-17,20-21,25,27-
28,30,32-39,42-45 two randomised placebo-controlled crossover 
trials;40,41 one single-blind, placebo-controlled trial;46 
one double-blind, randomised trial against an active 
component;32 six uncontrolled before-after trials;18,22-24,26,29 
one controlled before-after trial.19 Only one trial was a 
priori set up in a randomised placebo-controlled fashion 
to test solely whether garlic lowers blood pressure in a 
hypertensive population.16
Some trials lacked important data. Fourteen trials did not 
report any numerical blood pressure data. Two studies 
reported no demographic data,17,37 14 studies24,28-30,35,36-39,41-
42,44-46 did not explicitly exclude patients on hypertensive 
medication and in two trials such medication was 
allowed.27,33
table 3. Criteria for the judgement of the quality of the 
blood pressure measurement reported in the included 
trials (n=32)
Quality criterion number of studies 
fulfilling criterion
Blood pressure device and accuracy 
mentioned (yes/no)
6
Body position reported (yes/no) 13
Measurement with arm at heart level (yes/no) 0
Rest period before measurement (yes/no; at 
least 5 minutes)
7
Number of readings reported (yes/no; at least 2) 9
Comparison with earlier systematic reviews
We hypothesised that conclusions drawn by previous 
authors were based on differences in inclusion and 
exclusion criteria due to differences in evaluating trial 
quality. Methodological weaknesses were identified in 
the two earlier meta-analyses5,6 by examining if the trials 
included by these authors lacked our quality criteria. 
Because one previous review4 did not use a quality 
assessment this review was not included in the analysis.
r e s U l t s
Figure 1 shows the selection process. Of the 203 trials found 
through the initial database search, 165 possible garlic 
trials were identified. The crosschecking of references and 
reviews revealed another 17 trials.
A total of 137 studies did not meet the inclusion criteria. 
Another 13 trials were excluded for various reasons mentioned 
in figure 1. The remaining 32 trials were further analysed.15-46
study description
Table 4 describes the trials reporting on the effect of garlic 
on blood pressure. Sample size ranged from 2324 to 86218 
subjects and trials lasted from 823,29,46 to 15617 weeks. 
Fifteen trials had blood pressure as a primary objective16,19-
23,26,30-32,36-37,41,43,45 and 16 trials comprised of hypertensive 
patients.16,18-24,26-27,31-32,34-35,41,44 
figure 1. Flow diagram of the process of selecting 
clinical trials examining the effect of garlic ingestion 
on blood pressure
203 articles found through 
database searching
182 articles screened
45 articles included
32 articles evaluated
17 articles added via crosschecking 
references
137 not fulfilling inclusion criteria:
• 98 no garlic trial
• 1 participants <18 years
• 30 no blood pressure in results
• 8 trials lasting <8 weeks
13 articles later excluded:
• 5 language (Italian, Russian, Farsi)
• 2 Questionnaires
• 1 n=1 trial
• 1 tread mill trial
• 2 articles not found
• 2 double publications
38 duplicates removed
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table 4. Summary of the 32 clinical trials of more than eight weeks examining the effect of garlic ingestion on blood 
pressure
author (publication year) 
[reference number]
sample 
size 
Primary 
objective
Blood 
pressure
intervention (total 
daily intake in grams)
Control group 
(total daily intake 
in grams)
Co- 
interventions
trial length 
(in weeks)
Adler et al. (1997)15 50 LP N GP (0.9) PL Primrose oil 12 
Auer et al. (1990)16 47 LP + BP H GP (0.6) PL NG 12
Bordia et al. (1989)17 432 reinfarction NND GO (NND) PL NG 156
Brewitt et al.(1991)18 862 LP H GP (6-12) No placebo group NG 26
Cheng et al. (2006)19 79 LP +BP H GP (0.012) + diuretic Diuretic Diuretic 52
Czerny et al. (1996)20 100 LP + BP H GO (0.4) + lecithin PL NG 14 
De A Santos et al.(1993)21 60 LP + BP N + H GP (0.9) PL DA 24
De A Santos et al. (1995)22 80 LP + BP N + H GP (1.8) GO (0.006) NG 16
Dhawan et al. (2004)23 40 LP + BP N + H Garlic pearls (0.4) Garlic pearls (0.4) NG 8
Durak et al. (2004)24 23 LP N + H Garlic extract (10) No control group NG 16
Gardner et al. (2001)25 53 LP N GP (0.3-1.0) PL DA 12 
Grünwald et al. (1992)26 48 LP + BP N + H GP (0.6) No placebo group NG 18
Holzgartner et al. (1992)27 98 LP N + H GP (0.9) Bezafibrate (0.6) NG 12 
Isaacsohn et al. (1998)28 50 LP N GP (0.9) PL DA 12 
Jabbari et al (2005)29 50 LP N Raw garlic (1) Raw garlic (1) NG 8*
Jain et al. (1993)30 42 LP + BP N GP (0.9) PL NG 12 
Kandziora (1988)31 40 BP H GP (0.6) Diuretic-reserpin 
combination
Lifestyle 
advice
12 
Kandziora (1988)32 40 BP H GP (0.6) + diuretic PL + diuretic Low salt diet 12 
Kiesewetter et al. (1993)33 80 Pain-free 
walking 
distance
NND GP (0.8) PL Physio-
therapy
12
Lutomski (1984)34 102 NG N + H GP (0.3) + rutin PL NG 12
Macan et al. (2006)35 52 Warfarin 
safety
N + H Garlic solution (0.008) PL NG 12
Mansell et al. (1996)36 60 BP NND GP (0.9) PL NG 12
McMahon et al. (1992)37 42 BP NND GP (0.9) PL NG 12
Mrozikiewicz et al.(1988)38 NND NG NND GP (0.9/1.8) or GO (3) PL NG 12
Saradeth et al. (1994)39 72 LP N GP (0.6) PL NG 15
Simons et al. (1995)40 31 LP N GP (0.9) Lactose NG 12*
Steiner et al. (1996)41 52 LP + BP N + H GP (2.4) PL DA 24*
Superko et al. (2000)42 50 LP N GP (0.9) PL DA 12
Turner et al. (2004)43 75 LP + BP N GP (0.92) PL NG 12
Vorberg et al. (1990)44 40 NG N + H GP (0.9) PL NG 16
Zhang et al. (2000)45 36 BP N GO (0.012) PL NG 16
Ziaei et al. (2001)46 100 LP N GP (0.8) PL NG 8
BP = blood pressure; da = dietary advice with adequate instruction; Go = garlic oil; GP = garlic powder; H = hypertensive; lP = lipids;  
n = normotensive; nnd = no numerical data available; nG = data not given; Pl = placebo. *Crossover studies; only the first parallel arm.
methodological quality 
Figure 2 shows how well studies performed on the 
methodology scale. No trials scored maximum. The median 
score was four points (range 0-8). Eleven trials scored five or 
more points.21,25,27-28,30,33,35,40,43-45 Trials scored low for intention-
to-treat analysis, allocation concealment (i.e., shielding 
those who admit participants to a study from knowing the 
upcoming assignments) and for the blinding of evaluators. 
This is shown in table 2. Randomisation15-17,19-22,25,27-46 and 
providing the same treatment among treatment arms15-17,19-
23,28-46 were fairly well described in the selected studies.
Blood pressure measurement
Figure 3 depicts the spread of scores on reporting the five 
blood pressure criteria. Scoring was poor. Half of the 
trials did not report any criterion17-21,24,26-27,29,34-39,42,46 and 
only six trials scored three points or more.23,25,30,40,43,45 
A subdivision of the scoring system is shown in table 3. 
Information about the five criteria was scarce; no trial 
reported arm height during measurement and less than 
a quarter described the blood pressure device25,30,40,41,43,45 
or the resting period.23,25,30,33,40,43,45 Body position was most 
often cited.15,16,22-23,25,28,30-33,40,43-44 
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Comparison with earlier meta-analysis
Of the 32 studies, 13 have been studied by either Ried 
et al.6 or Silagy and Neil.5 The latter also included one 
study lasting less than eight weeks.47 The quality of 
these studies is summarised in table 5. All trials lack 
proper allocation concealment, blinding of evaluators 
and intention-to-treat analysis. Moreover, there was 
little information about the quality of blood pressure 
measurement. None of the trials provided information 
about arm height. Only two trials30,40 mentioned resting 
period, the device used, body position of the patient and 
number of readings.
Trials with highest scores in both our quality assessments 
are summarised in table 6. For clarity cutoff points of 5 
and 3 were used for the methodology score and the blood 
pressure score respectively. Garlic did not lower blood 
pressure in any selected trial. However, none of these trials 
were performed in hypertensive subjects. 
d i s C U s s i o n
Our main conclusion is that the hypotensive effect of garlic 
cannot be ascertained, because conclusions from previous 
meta-analyses have been based on trials with inadequate 
study designs, with methodological defects and with 
insufficient information on blood pressure measurement. 
Moreover, trials with the best methodology were performed 
in normotensive subjects.
This study shows that designs of trials on the effect of 
garlic on blood pressure have important flaws. Few trials 
used only hypertensive subjects. Only one trial was set 
up in a randomised, placebo-controlled, double-blind 
fashion to evaluate the effect of garlic on blood pressure in 
a hypertensive population. Although other study designs 
may be used, these are prone to the introduction of bias. 
Moreover, it may be questionable, but not entirely ruled 
out, that effects found in normotensive subjects can be 
extrapolated to hypertensive patients.
Secondly, the methodological quality was poor. No trials 
reported intention-to-treat analysis and only a minority 
had an adequate allocation concealment and blinding 
of evaluators. This is in agreement with two previous 
systematic reviews on the effect of garlic on blood 
pressure.4,5 Using another methodology scale, Silagy 
and Neil scored for randomisation, intention-to-treat 
analysis and for blinding of the evaluators.5 None of 
their eight included trials16,21,27,30,31-32,44,47 scored positive 
on all points and they therefore concluded that ‘quality 
assessment of the trials was generally poor’. These trials 
also scored weak in our rating scales (table 5). Another 
systematic review by Ackermann et al.4 did not perform 
a systematic quality analysis. However, they do provide 
some overview of trial quality mainly corroborating with 
our findings. Ackermann et al.4 refrained from carrying 
out a meta-analysis because ‘about half of the studies 
did not present numerical data, multiple blood pressure 
measurements were used and few studies had a priori 
hypotheses related to blood pressure.’
In trials on complementary medicine in general, others 
have also reported low methodological quality.7,48 Linde 
et al.7 reviewed trials on homeopathy, acupuncture and 
herbal medicine, garlic not included. They concluded that 
most trials had inadequate allocation concealment, poor 
randomisation procedures and gave little information about 
dropouts. In a more comprehensive review, Gagnier et al.48 
analysed 1321 English trials on herbal medicine, garlic 
included. They concluded that trials in herbal medicine 
provided less than half of the necessary information in 
their reports. Of the ten herbs studied, garlic trials scored 
second worst. Allocation concealment, randomisation and 
figure 2. Spread of quality scores on the methodology 
of the selected clinical trials (n=32)
0
0
2
6
14
10
4
12
8
16
N
um
be
r 
of
 s
tu
di
es
1 2 3 4
Points on quality scale
5 6 7 8 9
1
2
0
4
14
6
2
1
2
0
no points indicates a high suspicion of bias. the quality criteria are 
mentioned in table 2.
figure 3. Spread of scores of the quality of blood 
pressure measurement as reported in the selected 
clinical trials (n=32)
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blinding of the evaluators, as in the present study, were 
poorly described.
Our conclusion on the methodological quality contrasts 
with the work by Ried et al.6 however. In their systematic 
review they also used guidelines by the Cochrane 
Collaboration for assessing trial quality. They concluded 
on the basis of their analysis that trial quality of their 
included trials was ‘generally high’. However, they only 
provided information about blinding, randomisation and 
blood pressure as a primary outcome. Our analysis shows 
that what trials mostly lack is an adequate allocation 
concealment, blinding of the evaluators and proper use 
of an intention-to-treat analysis. It has been shown that 
inadequate allocation concealment or blinding may lead 
to exaggerated treatment effects.10,50,51 When taking into 
account all nine quality criteria, the performance of the 
included garlic trials is, at least, equivocal. 
The third conclusion that can be drawn from our results 
is that trials provide insufficient information about the 
technique used to measure blood pressure. The absence of 
proper information about blood pressure measurements is 
worrying since factors such as arm position may influence 
blood pressure measurements by up to 10 mmHg.12 The 
fact that only 15 studies had blood pressure as a primary 
outcome might explain this absence. One could argue it 
is not the blood pressure per se that counts but rather the 
difference between the measurements. However, incorrect 
table 5. Quality analysis of the 14 included trials in the meta-analyses performed by Ried et al.6 or by Silagy and Neil5
author (year) 
[reference]
included by ried 
(r) or silagy (s)
total points quality 
scale (max. 9)
lacking items total points blood 
pressure scale (max. 5)
lacking items
Adler (1997)15 R 4 AC, PB, EB, CG, IT 1 DM, AH, RP, NR
Auer 
(1990)16
R + S 4 AC, EB, CG, D, IT 1 DM, AH, RP, NR
De A Santos (1993)21 S 6 AC, EB, IT 0 DM, AH, BP, RP, NR, 
Holzgartner (1992)27 R + S 5 AC, EB, IT, ST 0 DM, AH, BP, RP, NR
Jain 
(1993)30
R + S 5 AC, EB, D, IT 4 AH
Kandziora (1988)31 S 4 AC, PB, EB, D, ITT 2 DM, AH, RP
Kandziora (1988)32 R + S 4 AC, EB, D, IT 2 DM, AH, RP
Kiesewetter*
(1991) 47
S 4 AC, EB, CG, D, IT 0 DM, AH, BP, RP, NR
Kiesewetter (1993)33 R 5 AC, EB, D, IT 2 DM, AH, NR
Saradeth 
(1994)39
R 4 AC, EB, CG, D, IT 0 DM, AH, BP, RP, NR
Simons (1995)40 R 5 AC, EB, CG, IT 4 AH
Steiner (1996)41 R 4 AC, EB, CG, D, IT 1 BP, AH, RP, NR
Vorberg (1990)44 R + S 5 AC, EB, CG, IT 1 DM, AH, RP, NR
Zhang (2000)45 R 6 AC, EB, D, IT 3 BP, AH
aC = allocation concealment; PB = patient blinding; eB = evaluators blinding; d = dropouts; CG = comparable groups; it = intention-to-treat 
analysis; st = same treatment of groups; dm = device mentioned; aH = arm at heart level; BP = body position; rP = resting period;  
nr = number of reading. *not included in our systematic review because of a treatment period of less than eight weeks.
table 6. Summary of the five clinical trials on the effect of garlic on blood pressure with the highest methodological 
quality score and highest score for the quality in reporting blood pressure measurements
author (year) [reference] Blood pressure a 
primary goal
Hypertensive 
population
methodological 
quality* 
Blood pressure 
quality**
Garlic effective in 
lowering blood pressure
Gardner (2001)25 No No 7 4 No
Jain (1993)30 No No 5 4 No
Simons (1995)40 No No 5 4 No
Turner (2004)43 Yes No 8 4 No
Zhang (2000)45 Yes No 6 3 No
*score based on the criteria proposed by the dutch Cochrane society. no points indicates a high suspicion of bias. a cutoff value of five points or 
more was chosen. **Blood pressure quality was scored on reporting on exact device, body position, arm at heart level, resting period and number 
of readings reported. a maximum of five point could be obtained. a cutoff value of three points was chosen.
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blood pressure measurements would inherently lead to 
data pollution of normotensive and hypertensive subjects 
making conclusions impossible. Besides, none of the 
studies included in the present review described that blood 
pressure was measured similarly every time.
To our knowledge, the present study is the first review 
that systematically assessed blood pressure measurement 
in garlic trials. Of the three previous systematic reviews 
on garlic and blood pressure, only Ried et al.6 provide 
data about blood pressure measurements, but they do not 
draw the conclusion that the information was insufficient. 
Roche et al.14 have reviewed the reporting of blood pressure 
measurements in leading English medical journals. In 
their analysis of 116 papers, device accuracy and validation 
or reporting of arm level was also poorly described; 
device accuracy was only reported in 3% and arm level 
in 5%. As in the present study, both body position and 
number of readings were best reported. Also in a review 
of Brazilian medical literature, Holanda et al.49 showed 
articles lacked important data; in only half of the studies 
the type of sphygmomanometer or the number of readings 
were mentioned and only a quarter described the body 
position.
Did the inclusion of these garlic trials affect the conclusions 
of previous meta-analyses? In our view the absence of a 
proper methodology may have indeed affected outcome. 
Both Schulz et al. and Moher et al. have shown that 
inadequate allocation concealment and lack of blinding 
may lead to exaggerated results.50,51 In the present study it 
was shown that garlic trials scored poorly in both criteria. 
Biased results in trials may also affect results of systematic 
reviews.10 According to the criteria put forward in the 
present study, only five trials provide sufficient quality data 
(table 6).25,30,40,43,45 These studies do not show an effect of 
garlic on blood pressure. We refrained from conducting a 
meta-analysis, however, because all trials were performed 
on normotensive subjects. In our view these trials are not 
suitable to answer the only clinically relevant question 
whether garlic lowers blood pressure in hypertensive 
patients.
Our analysis has several limitations. Our scoring systems 
inherently had some subjective elements. We minimised 
this effect by using two independent evaluators and a 
standardised checklist. Second, the absence of reporting 
procedures in the garlic trials does not necessarily imply 
these procedures were not done. Our criteria might 
have been biased towards precisely written studies. 
It is our opinion, though, that transparency is a key 
element in conducting trials. In such a way, clear writing 
might in itself be a quality criterion. Deficient reporting 
generally embodies imperfect methodologies.10 Thirdly, 
the applicability of scores to appraise the methodological 
quality has been challenged by others,8,10 arguing that 
high scores do not necessarily represent valid trials. They 
propose that relevant methodological aspects should be 
assessed individually.10 We therefore used both, because 
in our view an overall composite score nevertheless gives a 
pragmatic and visual tool for a global quality assessment.
C o n C l U s i o n
It is our view that garlic cannot be recommended to lower 
blood pressure in the daily practice of physicians working 
in the field of hypertension treatment, given the low 
methodological quality, the lack of information about blood 
pressure measurement and the absence of methodological 
sound trials in hypertensive patients. 
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